Statute Details
- Title: Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007
- Act Code: HPA2007-S683-2007
- Type: Subsidiary Legislation (SL)
- Authorising Act: Health Products Act 2007 (Act 15 of 2007), section 72 (read with regulation 1(l) of the Second Schedule)
- Enacting Authority: Health Sciences Authority (HSA), with Minister for Health approval
- Commencement: 1 January 2008
- Current version: Current version as at 27 Mar 2026 (per provided extract)
- Key Parts: Part I (Preliminary); Part II (Supply of Cosmetic Products); Part III (Advertisement of Cosmetic Products); Part IV (Additional Duties and Obligations)
- Key Provisions (from extract): Sections 1–3 (Citation/commencement; Definitions; Application)
- Other Key Provisions (from extract headings): Sections 4–11 (notification, contents, labelling, misleading labelling, advertisement, records, reporting defects/adverse effects)
- Schedules: First and Second Schedules repealed; Fourth Schedule contains standard references for cosmetic ingredient nomenclature
- Legislative amendments (timeline shown in extract): Amended by S 721/2010, S 43/2019, S 89/2019, S 453/2022, S 9/2023, S 682/2023, S 816/2024, S 768/2025
What Is This Legislation About?
The Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007 (“Cosmetic Regulations”) are Singapore’s regulatory framework for cosmetic products, designed to align with the ASEAN Cosmetic Directive. In practical terms, the Regulations set out compliance requirements for businesses that supply cosmetics in Singapore—covering notification to the regulator, product composition and ingredient-related rules, labelling and advertising controls, and ongoing post-market obligations such as record-keeping and reporting of defects and adverse effects.
Cosmetics are often perceived as lower-risk than medicines, but they can still cause harm through irritants, contaminants, or misleading claims. The Regulations therefore focus on ensuring that cosmetic products placed on the Singapore market meet defined standards and that the market is kept informed through proper labelling, truthful advertising, and timely reporting when problems arise.
Although the extract provided includes only the headings and some preliminary provisions, the structure of the Regulations is clear: Part II governs supply and product information; Part III governs advertising; and Part IV imposes additional duties on responsible parties after products are in circulation. The Regulations operate under the umbrella of the Health Products Act 2007, which provides the legislative authority and enforcement architecture.
What Are the Key Provisions?
1. Citation, commencement, and legislative purpose (Sections 1–3). Section 1 provides the citation and commencement date: the Regulations came into operation on 1 January 2008. This matters for compliance timelines—obligations such as notification, labelling, and record-keeping apply from the commencement date and thereafter, subject to any transitional provisions in amending instruments (not shown in the extract).
2. Definitions and the “person responsible” concept (Section 2). Section 2 defines “cosmetic product” by reference to the First Schedule to the Health Products Act 2007. This is a key drafting technique: rather than re-defining the product category in full, the Regulations “import” the statutory definition from the parent Act. For practitioners, this means classification work often requires reading both the Act and the Regulations together.
Section 2 also introduces a crucial compliance concept: the “person responsible for placing a cosmetic product in the market” is the person in Singapore who is instrumental in causing the cosmetic product to be available for sale in Singapore. This definition is central to enforcement. It identifies who must take regulatory steps (such as notification and ongoing obligations) even if the product is manufactured overseas. In cross-border supply chains, this “instrumental” test can be fact-sensitive; lawyers advising importers, distributors, and brand owners should map contractual and operational roles to determine who is likely to be treated as the responsible person.
3. Scope exclusions (Section 3). Section 3 provides that the Regulations do not apply to a cosmetic product that is (a) imported solely for re-export, or (b) manufactured in Singapore solely for export. This exclusion is important for logistics and trade compliance. It allows businesses to handle goods in transit or for foreign markets without triggering Singapore market obligations—provided the “solely” condition is met. Practically, companies should ensure their import/export documentation, warehousing practices, and commercial arrangements support the “solely for re-export/export” position.
4. Notification duty for supply (Section 4). Part II begins with a duty to notify the Authority of the supply of cosmetic products. While the extract does not reproduce the text of Section 4, the heading indicates a pre-market or at least supply-stage obligation. In Singapore’s regulatory pattern, “notification” typically requires submission of prescribed particulars (for example, product identity, ingredient information, and other details) to the regulator before or at the time of placing the product on the market. For counsel, the key is to confirm: (i) when notification must be made (before first supply vs. within a time window), (ii) what information is required, and (iii) whether updates are required when formulations or labels change.
5. Product contents, labelling, and misleading labelling (Sections 6–8). Part II also contains substantive requirements regarding the contents of cosmetic products (Section 6), labelling (Section 7), and misleading labelling (Section 8). These provisions are the backbone of consumer protection in the cosmetic context. “Contents” rules generally relate to permissible ingredients, restrictions, and compliance with ingredient standards. “Labelling” rules typically require that information be presented in a clear and prescribed manner (including ingredient listing, warnings where relevant, and other mandatory particulars). “Misleading labelling” targets claims or representations that could deceive consumers as to safety, performance, or composition.
For practitioners, these provisions create a compliance triad: (1) formulation/ingredient compliance, (2) packaging and label compliance, and (3) claims compliance. Even where a product’s ingredients are acceptable, non-compliant labelling or misleading claims can still trigger regulatory action. Lawyers should therefore advise clients to treat labelling and advertising as part of the overall product compliance system, not as a purely marketing exercise.
6. Advertisement controls (Section 9). Part III governs advertisement of cosmetic products. Advertising is often where regulatory risk concentrates because marketing materials may include performance claims, therapeutic-like statements, or exaggerated safety assurances. Section 9 likely requires that advertisements comply with prescribed standards and do not mislead. In practice, counsel should review not only traditional media (print, TV, radio) but also digital advertising, influencer campaigns, and e-commerce listings—each of which can be treated as “advertisement” depending on how the regulator interprets the term.
7. Record-keeping and post-market reporting (Sections 10–11). Part IV imposes ongoing obligations: a duty to maintain records of supply (Section 10) and reporting of defects and adverse effects to the Authority (Section 11). These provisions reflect a post-market surveillance approach. Record-keeping enables traceability—who supplied the product, when, in what quantities, and to whom. Reporting duties ensure that if a product causes harm or is found defective, the regulator can take action (for example, risk assessments, warnings, or enforcement measures).
From a legal risk perspective, these duties are critical for two reasons. First, they create compliance obligations that continue after initial notification and labelling approval. Second, they can become central in investigations following consumer complaints, adverse event reports, or media attention. Lawyers should therefore ensure clients implement robust complaint-handling, adverse event triage, and documentation systems that can support regulatory reporting within required timelines.
How Is This Legislation Structured?
The Regulations are organised into four main Parts and several Schedules.
Part I (Preliminary) contains the citation and commencement provision (Section 1), definitions (Section 2), and application/scope exclusions (Section 3). This Part sets the interpretive framework and identifies who is responsible and when the Regulations apply.
Part II (Supply of Cosmetic Products) covers the core market-entry and product compliance requirements: notification to the Authority (Section 4), product contents (Section 6), labelling (Section 7), and misleading labelling (Section 8). Section 5 is shown as deleted in the extract, indicating that the regulatory scheme has been amended over time.
Part III (Advertisement of Cosmetic Products) contains Section 9, focusing on how cosmetic products may be advertised.
Part IV (Additional Duties and Obligations) includes Section 10 (records of supply) and Section 11 (reporting defects and adverse effects). These provisions support traceability and post-market safety monitoring.
The Schedules include repealed schedules (First and Second) and a Fourth Schedule that sets out standard references used for cosmetic ingredient nomenclature. This is particularly relevant for ingredient listing and compliance with naming conventions.
Who Does This Legislation Apply To?
The Regulations apply to parties involved in supplying cosmetic products in Singapore, with compliance obligations anchored to the “person responsible for placing a cosmetic product in the market” (Section 2). In other words, the duty-holder is the Singapore person who is instrumental in making the product available for sale in Singapore. This can include importers, local distributors, brand owners, or other entities that control or drive market availability.
The Regulations do not apply to cosmetic products imported solely for re-export or manufactured in Singapore solely for export (Section 3). However, if a product is actually supplied for sale in Singapore, the exclusion will not generally protect the supply chain. Lawyers should therefore assess the commercial facts: whether goods are truly “solely” for re-export/export, and whether any diversion to the Singapore market could undermine the exclusion.
Why Is This Legislation Important?
For practitioners, the Cosmetic Regulations are important because they operationalise Singapore’s cosmetic compliance regime in a way that is both consumer-protection focused and supply-chain practical. The Regulations require businesses to engage with the regulator (through notification), ensure product and label compliance, control misleading claims, and maintain traceability and safety reporting after products enter the market.
From an enforcement perspective, the combination of labelling/advertising controls and post-market reporting duties creates multiple compliance “touchpoints” where regulatory action can be triggered. For example, a product may be formulation-compliant but still breach the Regulations if its label or advertising is misleading. Conversely, a product may be properly labelled but still create regulatory exposure if adverse effects are not reported or if records cannot be produced during an investigation.
Finally, the ASEAN alignment aspect matters for multinational businesses. Companies operating across ASEAN markets often seek harmonised compliance approaches. While the Regulations are Singapore-specific, the ASEAN Cosmetic Directive influence can affect how ingredient standards, labelling expectations, and safety reporting practices are interpreted. Counsel advising regional brands should therefore consider whether their ASEAN compliance framework can be adapted to Singapore requirements, while still verifying Singapore-specific notification and reporting mechanics.
Related Legislation
- Health Products Act 2007 (Act 15 of 2007) — the authorising Act; provides the overarching regulatory framework and definitions (including the cosmetic product definition via the First Schedule to the Act)
Source Documents
This article provides an overview of the Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.